ENEFIN 20 мг/12,5 мг Таблетки

Содержание инструкции

1. Enefin 20 mg + 12,5 mg tablets
   1. What Enefin is and what it is used for
   2. What you need to know before taking Enefin
   3. How to take Enefin
   4. Possible side effects
   5. How to store Enefin
   6. Contents of the pack and other information

Enefin 20 mg + 12,5 mg tablets

enalapril maleate + hydrochlorothiazide

Read this leaflet carefully before you start taking this medicine as it contains
important information for you.

• Keep this leaflet. You may need to read it again.
• If you have any questions, ask your doctor or pharmacist.
• This medicine has been prescribed for you only. Do not pass it on to others, even if their symptoms are the same as yours, as it may be harmful.
• If you get any side effects, even those not listed in this leaflet, tell your doctor or pharmacist. See section 4.

Contents of this leaflet:

• 1. What Enefin is and what it is used for
• 2. What you need to know before you take Enefin
• 3. How to take Enefin
• 4. Possible side effects
• 5. How to store Enefin
• 6. Contents of the pack and other information

1. What Enefin is and what it is used for

Enefin contains two active ingredients: enalapril maleate and hydrochlorothiazide.
Enalapril maleate belongs to a group of medicines known as angiotensin converting enzyme (ACE) inhibitors. ACE inhibitors work by causing the relaxation
of blood vessels, and therefore facilitating the passage of blood through them. ACE inhibitors
are used for the treatment of high blood pressure (hypertension).
Hydrochlorothiazide belongs to a group of medicines called thiazide diuretics. It works
by stimulating the kidneys to produce a greater quantity of urine (diuretic action) and thus reducing the
blood pressure (antihypertensive action).
Enefin is used for the treatment of high blood pressure and is indicated in patients whose
blood pressure is not adequately controlled with enalapril maleate or hydrochlorothiazide
administered alone.

2. What you need to know before taking Enefin

Do not take Enefin:

• if you are allergic to the active ingredients (enalapril maleate and hydrochlorothiazide) or to other medicines derived from sulfonamide (a chemically related substance to hydrochlorothiazide), or to any of the other ingredients of this medicine (listed in section 6);
• if you have had an allergic reaction that caused swelling of the hands, feet, ankles, or even the face, lips, tongue and/or throat with resulting difficulty swallowing or breathing (angioedema) after taking ACE inhibitors;
• if you suffer from hereditary angioedema (due to a family history);
• if you suffer from idiopathic angioedema, i.e. angioedema whose cause is unknown;
• if you suffer from severe kidney problems (severe renal failure);
• if you are unable to urinate (anuria);
• if you are in the second or third trimester of pregnancy (see section “Pregnancy and breastfeeding”);
• if you suffer from severe liver problems (severe hepatic failure);
• if you suffer from diabetes or your kidney function is impaired and you are being treated with a medicine that lowers blood pressure, containing aliskiren (see section “Other medicines and Enefin”);
• if you are being treated with sacubitril/valsartan, a medicine for heart failure.

Warnings and precautions
Talk to your doctor or pharmacist before taking Enefin.
In particular, talk to your doctor or pharmacist before taking Enefin if:

• you are taking medicines that increase urine production (diuretics), are following a low-salt diet, or if you have had vomiting or diarrhea. In these cases you are at risk of an excessive drop in blood pressure (hypotension) which can manifest with a feeling of weakness or dizziness. Your doctor will prescribe you to measure the amount of electrolytes in your blood regularly;
• you have disturbances of blood flow to the heart (ischemic heart disease) or brain (ischemic cerebrovascular disease), or other heart problems associated with or without kidney problems. In these cases, an excessive lowering of blood pressure can be particularly dangerous. If you experience symptoms of hypotension during treatment with Enefin, lie down and contact your doctor;
• you have had skin cancer in the past or if you are developing an unexpected skin lesion during treatment. Treatment with hydrochlorothiazide, especially long-term use with high doses, can increase the risk of certain types of skin cancer and lips (non-melanoma skin cancer). Protect your skin from exposure to the sun and UV rays while taking Enefin;
• inform your doctor if you are taking a medicine containing a neprilysin inhibitor such as sacubitril (available as a fixed-dose combination with valsartan), used in patients with heart failure, and racecadotril, used in patients with acute diarrhea;
• you are taking one of the following medicines used to treat high blood pressure:
• an “angiotensin II receptor antagonist” (AIIRA) (also known as sartans - for example valsartan, telmisartan, irbesartan), especially if you have kidney problems related to diabetes;
• aliskiren. Your doctor may check your kidney function, blood pressure, and the amount of electrolytes (e.g. potassium) in your blood at regular intervals. See also what is stated in the section “Do not take Enefin”;
• you are at risk of an increase in potassium levels in the blood (hyperkalemia) due to:
• renal failure, worsening of kidney function, age over 70 years, diabetes, dehydration, acute heart failure due to the heart not pumping blood adequately throughout the body, increased acidity in the blood (metabolic acidosis);
• concomitant use of medicines that facilitate urine excretion while preserving potassium (potassium-sparing diuretics, for example spironolactone, eplerenone, triamterene or amiloride), potassium supplements, salt substitutes containing potassium, or if you are taking other medicines that can increase potassium in the blood (e.g., heparin [a medicine used to prevent blood clots], products containing trimethoprim such as co-trimoxazole [medicines used to treat infections]) (see section “Other medicines and Enefin”). In such cases, your doctor will frequently monitor the potassium level in your blood;
• you suffer from a narrowing (stenosis) of the aortic artery or have a thickening of the heart walls (hypertrophic cardiomyopathy);
• you suffer from severe heart problems (severe heart failure);
• you have kidney problems, such as a narrowing (stenosis) of one or both renal arteries, as there is an increased risk of hypotension and renal failure. In this case, your doctor will keep you under close observation monitoring your kidney function;
• you have recently undergone a kidney transplant. In this case, the use of this medicine is not recommended;
• you are undergoing dialysis (blood purification therapy) due to renal failure. In this case, your doctor will consider alternative treatment (see section “Do not take Enefin”);
• you have liver problems or suffer from a disease that could lead to destruction of liver cells (progressive liver disease) (see sections “Do not take Enefin” and “Stop taking Enefin and tell your doctor if”);
• you have a chronic and degenerative liver disease (liver cirrhosis), have a marked urine production, do not take an adequate amount of electrolytes orally, are being treated with corticosteroids or adrenocorticotropic hormone (hormonal medicines). In these cases, the risk of a lowering of the potassium level in the blood (hypokalemia) is maximum;
• you suffer from a connective tissue disease involving blood vessels, are taking medicines that suppress the immune defenses (immunosuppressants), suffer from gout or are taking allopurinol (used in the treatment of gout) or procainamide (used to treat heart rhythm abnormalities), or have a combination of these risk factors, especially if you also have kidney problems. In this case, serious infections may occur that may not respond to antibiotic therapy. If you need to take Enefin in the presence of these conditions, your doctor will prescribe specific blood tests. Report any signs or symptoms of infection to your doctor;
• you have diabetes and are taking oral antidiabetic medicines or insulin. In this case, your doctor will tell you to undergo blood tests to check your glucose level, especially during the first month of treatment with Enefin and assess the need to adjust the dose of antidiabetic medicines;
• you are taking lithium (medicine for the treatment of mood disorders) (see section “Other medicines and Enefin”);
• you are of black race. Enefin may in fact be less effective in lowering blood pressure in patients of black race compared to patients of non-black race. In addition, you may have an increased risk of developing angioedema;
• you have developed a persistent dry cough for a long period of time after starting treatment with an ACE inhibitor;
• you have a history of allergies or bronchial asthma, as sensitivity reactions may occur with the use of Enefin;
• you suffer from a condition called systemic lupus erythematosus (an autoimmune disease), which may occur or worsen with the use of Enefin;
• you have decreased vision or eye pain. These may be symptoms of fluid accumulation in the vascular layer of the eye (choroidal effusion) or increased pressure in the eye and can occur within hours to weeks of taking ENEFIN. This condition can lead to permanent vision loss if left untreated. If you have had episodes of allergy to penicillin or sulfonamides in the past, you may be at higher risk of developing this condition.

If you are about to undergo one of the following procedures, tell your doctor that you are
taking Enefin:

• any surgical intervention or if you are to undergo anesthetic therapy;
• a treatment called LDL (low-density lipoprotein) apheresis with dextran sulfate, to remove cholesterol from the blood using machinery. Your doctor may interrupt the treatment with Enefin to prevent a possible allergic reaction;
• a treatment to reduce the effects of an allergy, resulting for example from an insect sting (desensitization treatment). If you take Enefin while undergoing this treatment, you may experience a severe allergic reaction, so it is advisable to temporarily interrupt the therapy;
• you need to undergo tests to check the function of the parathyroid glands. Consult your doctor who will tell you to stop taking Enefin before undergoing this test.

Stop taking Enefin and tell your doctor if you experience:

• swelling of the hands, feet, ankles, or even the face, lips, tongue and/or throat with resulting difficulty swallowing or breathing (angioedema);
• yellowing of the skin and the whites of the eyes (jaundice), which indicates liver problems or an increase in liver enzyme (transaminase) levels in the blood;
• increased levels of nitrogen and creatinine in the blood, this circumstance may suggest a stenosis of the renal artery;
• increased calcium levels in the blood (hypercalcemia). During treatment with Enefin, an electrolyte imbalance may occur which manifests with signs and symptoms that may include:
• dry mouth, thirst, weakness, deep sleepiness (lethargy), drowsiness, agitation, muscle pain or cramps, muscle fatigue, low blood pressure, reduced urine production, increased heart rate (tachycardia) and gastrointestinal disorders, such as nausea and vomiting. In these cases, inform your doctor promptly. The use of this medicine must occur under regular medical supervision. Therefore, strictly follow the examinations and laboratory tests prescribed by your doctor.

Children and adolescents
The use of Enefin is not recommended in children, due to the lack of safety and
efficacy data.

Other medicines and Enefin
Tell your doctor or pharmacist if you are taking, have recently taken or might take
any other medicine.
In particular, tell your doctor or pharmacist if you are taking:

• an angiotensin II receptor blocker (AIIRA) or aliskiren (see also what is reported in the paragraphs “Do not take Enefin” and “Warnings and precautions”). Your doctor may need to adjust your dose and/or take other precautions;
• other medicines that lower blood pressure (antihypertensives), including vasodilators, nitroglycerin and other nitrates, because an excessive reduction in blood pressure may occur;
• lithium, used for the treatment of some mood disorders, because an excessive increase in lithium concentration in the blood and subsequent lithium toxicity may occur;
• medicines that promote urine excretion while preserving potassium (potassium-sparing diuretics, for example spironolactone, triamterene or amiloride), potassium supplements, salt substitutes containing potassium or other medicines that can increase potassium in the blood (e.g., heparin [a medicine used to prevent blood clots], products containing trimethoprim such as cotrimoxazole [medicines used for the treatment of infections]) (see the paragraph “Warnings and precautions”);
• medicines that promote diuresis (diuretics), such as thiazides or loop diuretics, because they may cause a reduction in blood pressure;
• anaesthetics, antipsychotics and tricyclic antidepressants (used for the treatment of mental disorders) because a further reduction in blood pressure may occur;
• medicines that act on the autonomic nervous system (sympathomimetics) such as ephedrine, pseudoephedrine, salbutamol which are found in some nasal decongestants, in cough and cold medicines, for asthma, for the treatment of low blood pressure and for the treatment of heart problems. These medicines can reduce the antihypertensive effects of Enefin;
• insulin or other antidiabetic medicines taken orally. The blood glucose level should be carefully monitored, especially during the first weeks of treatment with Enefin and in patients with kidney problems;
• medicines used for the treatment of stiffness and inflammation associated with painful conditions, in particular those affecting muscles, bones and joints, including:
• medicines containing gold administered by injection, for example sodium aurothiomalate, because they can cause flushing of the face, feeling unwell (nausea), vomiting and low blood pressure, if taken with Enefin;
• non-steroidal anti-inflammatory drugs (NSAIDs), including COX-2 inhibitors, because they can reduce the effectiveness of Enefin, increase potassium levels in the blood and worsen kidney function;
• carbenoxolone (a medicine used to treat stomach problems such as ulcers), kaliuretic diuretics (for example furosemide) or excessive use of laxatives. The use of Enefin with these medicines may further reduce potassium and/or magnesium levels in the blood;
• tubocurarine, used to relax muscles during surgery (muscle relaxant), because Enefin can increase its effects;
• barbiturates, which have a sedative effect on the central nervous system, used for example to treat epilepsy, or opioid analgesics, medicines used to reduce pain. These medicines can worsen the feeling of dizziness when getting up, due to a lowering of blood pressure (orthostatic hypotension);
• medicines used to reduce the amount of fat in the blood, such as cholestyramine or colestipol resins because they can reduce the absorption of Enefin;
• medicines used to treat irregular heartbeat (antiarrhythmics such as quinidine, procainamide, amiodarone, sotalol) because they can cause heart rhythm problems (torsade de pointes);
• medicines used for the treatment of heart failure (digitalis medicines);
• corticosteroids (which modulate anti-inflammatory reactions) and adrenocorticotropic hormone ACTH (used to check if the adrenal glands are functioning properly) because they can further reduce salt levels in the blood, in particular potassium (hypokalemia);
• pressor amines (for example noradrenaline) because Enefin can decrease their effects;
• cancer medicines such as cyclophosphamide or methotrexate because Enefin can increase their toxicity;
• medicines to treat gout, such as allopurinol (see paragraph “Warnings and precautions”);
• medicines that suppress the immune system (immunosuppressants);
• mTOR inhibitors (e.g., temsirolimus, sirolimus, everolimus) as concomitant administration may increase the risk of an allergic reaction called angioedema (see the paragraph “Stop taking Enefin and tell your doctor if”).
• a medicine containing a neprilysin inhibitor such as sacubitril (available as a fixed-dose combination with valsartan) and racecadotril. The risk of angioedema (swelling of the face, lips, tongue or throat with difficulty swallowing or breathing) may be increased. See also the information contained in the paragraphs “Do not take ENEFIN” and “Warnings and precautions”.

Enefin and alcohol
Enefin should not be taken together with alcohol, as an excessive
reduction in blood pressure may occur.

Pregnancy and breastfeeding
If you are pregnant, suspect you are pregnant or are planning a pregnancy, or if you are breastfeeding with
breast milk, ask your doctor or pharmacist for advice before using this medicine.

Pregnancy
Enefin is not recommended during pregnancy, and should not be taken if you are pregnant for more than 3 months, as it can cause serious harm to the baby if taken after the third month of
pregnancy (see paragraph “Do not take Enefin”).
You should tell your doctor if you think you are pregnant (or if you are planning a
pregnancy). Your doctor will tell you to stop taking Enefin immediately before starting
pregnancy or as soon as you find out you are pregnant and will advise
you to take another medicine instead of Enefin.

Breastfeeding
Tell your doctor if you are breastfeeding or intend to breastfeed your baby with breast
milk. Enefin is not recommended in women who are breastfeeding, especially if your
baby was born prematurely and in the first few weeks after delivery.

Driving and operating machinery
Enefin can cause side effects that can affect your ability to drive and
operate machinery, such as dizziness or fatigue that may occur occasionally.
Therefore, be careful when driving and operating machinery.

Enefin contains lactose
If your doctor has diagnosed you with intolerance to certain sugars, contact him before taking
this medicine.

For athletes
The use of the medicine without therapeutic need constitutes doping and may still
result in positive doping tests.

3. How to take Enefin

Take this medicine following exactly the instructions of your doctor. If you have any doubts, consult your
doctor.
It is advisable to start therapy with ½ tablet a day. Subsequently, the recommended dose is
1 tablet a day. If necessary, your doctor may increase the dose up to a maximum of 2
tablets, administered once a day.

Previous diuretic therapy
If you are already taking another medicine that promotes diuresis, the use of enalapril, contained in
Enefin, may determine an excessive reduction in blood pressure. In such cases, if your
doctor still considers the use of Enefin necessary, they will tell you to suspend the diuretic a few
days before taking Enefin. If this is not possible, the doctor will decide to start therapy
with lower doses of enalapril, i.e. with separate tablets of the same active ingredients as Enefin
(enalapril and hydrochlorothiazide). Enefin can be used later, when the doctor has established
for you the need to take the dose of enalapril and hydrochlorothiazide present in the tablet of
Enefin.

Patients with kidney problems (renal insufficiency)
You must not use Enefin if you suffer from severe kidney problems (see section “Do not take Enefin”).
If you have kidney problems, your doctor will check your kidney function and decide the appropriate
dose of Enefin.

Use in children and adolescents
The use of Enefin is not recommended in children.

Use in the elderly
No dosage adjustment is necessary in elderly patients.

If you take more Enefin than you should
In case of accidental intake of an excessive dose of Enefin, immediately inform your doctor or
go to the nearest hospital and stop treatment.
The symptoms of an overdose may include: feeling of lightheadedness or dizziness, due to an
excessive lowering of blood pressure, serious circulation problems (circulatory shock), renal
insufficiency, hyperventilation, increased heart rate (tachycardia), palpitations, decreased heart
rate (bradycardia), anxiety, cough, electrolyte disturbances such as low levels of potassium
(hypokalaemia), chlorine (hypochloraemia) and sodium (hyponatraemia) in the blood, dehydration
due to excessive diuresis.

If you forget to take Enefin
Do not take a double dose to make up for the missed tablet. If in doubt
contact your doctor.

If you stop taking Enefin
Do not stop treatment with Enefin unless your doctor tells you to.
If you have any doubts about the use of this medicine, ask your doctor.

4. Possible side effects

Like all medicines, this medicine can cause side effects, although not everybody gets them.

Stop taking Enefin and consult your doctor immediately if you experience symptoms of angioedema during treatment, such as:

• allergic reaction accompanied by swelling of the hands, feet, ankles, or even the face, lips, tongue and/or throat with resulting difficulty swallowing or breathing (angioedema).

The side effects observed with the use of Enefin have been:

Very common (may affect more than 1 in 10 people)

• blurred vision;
• dizziness;
• cough;
• nausea;
• loss of strength (asthenia).

Common (may affect up to 1 in 10 people)

• lowering of the level of potassium in the blood (hypokalaemia) or increase of the level of potassium in the blood (hyperkalaemia), increase of the level of cholesterol, triglycerides, uric acid (hyperuricemia) and creatinine in the blood;
• headache, depression, temporary loss of consciousness (syncope), altered taste;
• lowering of blood pressure (hypotension), decrease in blood pressure when suddenly moving from a sitting or lying position to an upright position (orthostatic hypotension), changes in heart rhythm, pain accompanied by a sensation of constriction and oppression in the chest (angina pectoris), increased heart rate (tachycardia);
• difficulty breathing (dyspnea);
• diarrhea, abdominal pain;
• skin rash (exanthema);
• involuntary muscle contractions (muscle cramps);
• chest pain, fatigue.

Uncommon (may affect up to 1 in 100 people)

• decrease in the number of red blood cells (anemia, including aplastic and hemolytic anemia);
• decrease in blood sugar (hypoglycemia), decrease in the level of magnesium in the blood (hypomagnesemia), pain and swelling in the joints (gout);
• confusion, drowsiness, insomnia, nervousness, tingling sensation in the legs, arms or other parts of the body (paresthesia), feeling of dizziness (vertigo);
• reduced sexual desire, impotence;
• annoying sensation of sounds or whistling in the ears (tinnitus);
• redness and sensation of warmth mainly on the face (hot flashes), perception of irregular or reinforced heartbeat (palpitations), heart attack (myocardial infarction) or stroke (cerebrovascular accident) possibly secondary to a drastic drop in blood pressure in high-risk patients (see section “Warnings and precautions”);
• runny nose (rhinorrhea), burning in the throat (laryngodynia) and hoarseness, feeling of tightness in the chest that makes breathing difficult and noisy (bronchospasm/asthma);
• reduction of intestinal movements (ileus), inflammation of the pancreas (pancreatitis), vomiting, difficulty digesting food (dyspepsia), constipation, loss of appetite (anorexia), irritation of the stomach, dry mouth, lesions in the stomach (peptic ulcer), increased production of intestinal gas (flatulence);
• increased sweating (diaphoresis), itching, hives, hair loss (alopecia);
• joint pain (arthralgia);
• altered kidney function, kidney failure, presence of protein in the urine (proteinuria);
• illness, fever;
• increased level of urea in the blood (uremia), low sodium concentration in the blood (hyponatremia).

Rare (may affect up to 1 in 1,000 people)

• decrease in the number of some white blood cells (neutropenia, leukopenia and agranulocytosis), the amount of hemoglobin, the total volume of red blood cells (low hematocrit), platelets (thrombocytopenia) or all different types of blood cells (pancytopenia), bone marrow depression (when the bone marrow fails to produce a sufficient number of cells found in the blood), swelling of glands called lymph nodes (lymphadenopathy), diseases of the immune system (autoimmune diseases);
• increased blood sugar levels;
• abnormal dreams, sleep disorders, partial reduction of motility (paresis due to hypokalemia);
• reduced blood flow to the fingers of hands and feet causing redness and pain (Raynaud's phenomenon);
• lung problems including lung infiltrates, severe respiratory failure (acute respiratory distress syndrome), inflammation (pneumonia) and fluid accumulation in the lungs (pulmonary edema), allergic (hypersensitivity) reaction in the lungs (allergic alveolitis), lung disease (eosinophilic pneumonia);
• irritation or inflammation of the nose (rhinitis);
• inflammation of the oral mucosa (stomatitis) with ulcerations or sores, inflammation of the tongue (glossitis);
• liver problems such as liver failure, liver damage (necrotic hepatitis, potentially fatal), inflammation of the liver or bile ducts (hepatocellular or cholestatic hepatitis), yellowing of the skin and the whites of the eyes (jaundice), inflammation of the gallbladder (cholecystitis, especially in patients with pre-existing gallstones);
• severe skin diseases with blister formation, redness and peeling, including erythema multiforme, Stevens-Johnson syndrome, exfoliative dermatitis, toxic epidermal necrolysis, purpura, cutaneous lupus erythematosus (an autoimmune disease that causes skin inflammation), pemphigus and erythrodermia (redness of the skin);
• decreased urine output (oliguria), kidney disease (interstitial nephritis);
• growth of breast tissue in men (gynecomastia);
• increased liver enzymes, increased level of bilirubin in the blood (bilirubinemia).

Very rare (may affect up to 1 in 10,000 people)

• increased level of calcium in the blood (hypercalcemia);
• swelling of the intestinal mucosa (intestinal angioedema).

Not known (frequency cannot be estimated on the basis of available data):

• syndrome of inappropriate antidiuretic hormone secretion, SIADH;
• Decreased vision or eye pain due to high pressure (possible signs of fluid accumulation in the vascular layer of the eye (choroidal effusion) or acute angle-closure glaucoma)
• skin and lip cancer (non-melanoma skin cancer).

Other side effects
A complex disorder including one or more of the following symptoms has been reported, with unknown frequency:

• fever, serositis (inflammation of the membranes lining the body cavities, such as the chest and abdomen), vasculitis (inflammation of blood vessels), muscle pain or inflammation of the muscles (myalgia/myositis), pain or inflammation in the joints (arthralgia/arthritis), positive test for the presence of antinuclear antibodies, increased erythrocyte sedimentation rate (ESR), increased number of white blood cells (eosinophilia, leukocytosis), skin rash, skin sensitivity to light (photosensitivity) and other skin problems.

Reporting of side effects
If you get any side effects, even those not listed in this leaflet, tell your
doctor or pharmacist. You can also report side effects directly through
the national reporting system at
http://www.agenziafarmaco.gov.it/content/come-segnalare-una-sospetta-reazione-avversa.
By reporting side effects you can help provide more information on the safety
of this medicine.

5. How to store Enefin

Keep this medicine out of the sight and reach of children.
Do not use this medicine after the expiry date which is stated on the package and blister after
“Exp”. The expiry date refers to the last day of that month.
Store at a temperature not exceeding 30°C
Do not dispose of any medicine in wastewater or household waste. Ask your pharmacist how to
dispose of medicines you no longer use. This will help protect the environment.

6. Contents of the pack and other information

What Enefin contains

• The active ingredients are enalapril maleate and hydrochlorothiazide. Each tablet contains 20 mg of enalapril maleate and 12.5 mg of hydrochlorothiazide.
• The other excipients are: sodium bicarbonate, lactose monohydrate, yellow iron oxide, corn starch, pregelatinized starch, magnesium stearate.

Description of the appearance of Enefin and contents of the pack
Enefin is presented in the form of tablets contained in an aluminum blister.
Each pack contains 14 tablets.

Marketing authorisation holder and manufacturer
Marketing authorisation holder
LANOVA FARMACEUTICI S.r.l.
Via Conca D’oro, 212 – 00141 Roma
00189 Roma

Manufacturer
FARMAR ITALIA Via Zambelletti, 25 – Baranzate (Milano)
LACHIFARMA S.r.l. Laboratorio Chimico Farmaceutico Salentino
S.S. 16 Zona Industriale
73010 Zollino (LE)